Aggrenox Prevention of Access Stenosis

Summary

The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs primary unassisted patency in newly created arteriovenous grafts. This record previously included information for both the GRAFT and FISTULA trials.

Conditions

• Kidney Failure

Interventions

DRUG

Aggrenox

DRUG

Placebo

Sponsors & Collaborators

• The Cleveland Clinic

  collaborator OTHER

• Boston University

  collaborator OTHER

• Duke University

  collaborator OTHER

• University of Iowa

  collaborator OTHER

• MaineHealth

  collaborator OTHER

• University of Texas Southwestern Medical Center

  collaborator OTHER

• University of Alabama at Birmingham

  collaborator OTHER

• Washington University School of Medicine

  collaborator OTHER

• Baystate Medical Center

  collaborator OTHER

• Vanderbilt University

  collaborator OTHER

• CAMC Health System

  collaborator OTHER

• Emory University

  collaborator OTHER

• St. Louis University

  collaborator OTHER

• Tyler Nephrology Associates

  collaborator UNKNOWN

• Vascular Surgery Associates LLC

  collaborator OTHER

• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

  lead NIH

Principal Investigators

• John W Kusek, Ph.D. · NIDDK - Telephone: 301-594-7717; Email: [email protected]

• Catherine Meyers, M.D. · NIDDK - Telephone: 301-451-4901; Email: [email protected]

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2003-01-01

Primary Completion

2008-01-31

Completion

2008-01-31

FDA Drug

Yes

Countries

• United States

Study Locations